U.S. markets closed

Cipla Limited (CIPLA.NS)

NSE - NSE Real Time Price. Currency in INR
Add to watchlist
960.15-0.75 (-0.08%)
At close: 3:29PM IST
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close960.90
Open958.00
Bid0.00 x 0
Ask0.00 x 0
Day's Range950.50 - 962.70
52 Week Range621.05 - 982.30
Volume1,625,436
Avg. Volume6,650,613
Market Cap774.454B
Beta (5Y Monthly)0.46
PE Ratio (TTM)32.23
EPS (TTM)29.79
Earnings DateAug 05, 2021 - Aug 09, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateMar 19, 2020
1y Target Est592.05
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Moderna Sees Single-Dose COVID-19 Vaccine Launch In India In 2022
      Benzinga

      Moderna Sees Single-Dose COVID-19 Vaccine Launch In India In 2022

      Moderna Inc (NASDAQ: MRNA) expects to launch a single-dose COVID-19 vaccine in India in 2022 and is in talks with Cipla, among other Indian firms, reports Economic Times. While Moderna has conveyed to Indian authorities that it does not have surplus vaccines to share in 2021. Also, Johnson & Johnson (NYSE: JNJ) has limited prospects to export its COVID-19 vaccine outside the U.S., according to undisclosed sources. Cipla has already evinced interest in procuring 50 million doses from Moderna for 2022 and has requested confirmation from the central government. Today, Moderna said that its vaccine is effective for 12 to 17 year-olds; it will seek FDA approval. Meanwhile, Pfizer Inc (NYSE: PFE) is ready to offer 50 million shots in 2021, but it wants significant regulatory relaxations, including indemnification. The company has indicated availability of 50 million vaccine doses — 10 million each in July and August, 20 million in September, and 10 million in October. However, Pfizer said it would deal only with the Government of India, and payment for vaccines will have to be made by GOI to Pfizer India. Price Action: MRNA shares are up 2.8% at $168.75 during the market session on the last check Tuesday. See more from BenzingaClick here for options trades from BenzingaModerna's COVID-19 Vaccine Effective at Preventing Infection in AdolescentsSanofi, Walvax COVID-19 Vaccine Phase 3 Trials to Commence in Mexico: Reuters© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    • Reuters

      UPDATE 2-Eli Lilly signs deals to boost supply of COVID-19 treatment in India

      Eli Lilly and Co said on Monday it had signed licensing agreements with three Indian generic drugmakers to expand the availability of its arthritis drug baricitinib in the country for treating COVID-19 patients. The agreements will bolster India's arsenal of drugs to battle its catastrophic second wave of the pandemic, which has led to an acute shortage of coronavirus medicines including remdesivir and tocilizumab. The three Indian drugmakers - Cipla Ltd, Lupin Ltd and Sun Pharma - will collaborate with U.S.-based Lilly to help make and sell baricitinib in India.

    • Eli Lilly signs deals to boost supply of COVID-19 treatment in India
      Reuters

      Eli Lilly signs deals to boost supply of COVID-19 treatment in India

      BENGALURU (Reuters) -Eli Lilly and Co said on Monday it had signed licensing agreements with three Indian generic drugmakers to expand the availability of its arthritis drug baricitinib in the country for treating COVID-19 patients. The agreements will bolster India's arsenal of drugs to battle its catastrophic second wave of the pandemic, which has led to an acute shortage of coronavirus medicines including remdesivir and tocilizumab. The three Indian drugmakers - Cipla Ltd, Lupin Ltd and Sun Pharma - will collaborate with U.S.-based Lilly to help make and sell baricitinib in India.